These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38679213)

  • 41. Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis.
    Antinarelli LMR; Souza MVN; Coelho EAF; Lima WP; Coimbra ES
    Rev Soc Bras Med Trop; 2020; 53():e20200091. PubMed ID: 32578713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
    Tavares GSV; Mendonça DVC; Miyazaki CK; Lage DP; Soyer TG; Carvalho LM; Ottoni FM; Dias DS; Ribeiro PAF; Antinarelli LMR; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Parasitol Int; 2019 Feb; 68(1):63-72. PubMed ID: 30339837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
    Freitas EO; Nico D; Alves-Silva MV; Morrot A; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004297. PubMed ID: 26701750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Topical Treatment with (-)-Epigallocatechin Gallate, A Green Tea Catechin, in Mice with Cutaneous Leishmaniasis.
    Sosa AM; Moya Álvarez A; Bracamonte E; Korenaga M; Marco JD; Barroso PA
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290128
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
    Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SB-83, a 2-Amino-thiophene derivative orally bioavailable candidate for the leishmaniasis treatment.
    Rodrigues KADF; Silva DKF; Serafim VL; Andrade PN; Alves AF; Tafuri WL; Batista TM; Mangueira VM; Sobral MV; Moura RO; Mendonça Junior FJB; Oliveira MR
    Biomed Pharmacother; 2018 Dec; 108():1670-1678. PubMed ID: 30372869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
    Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leishmania (L). amazonensis induces hyperalgesia in balb/c mice: Contribution of endogenous spinal cord TNFα and NFκB activation.
    Borghi SM; Fattori V; Ruiz-Miyazawa KW; Miranda-Sapla MM; Casagrande R; Pinge-Filho P; Pavanelli WR; Verri WA
    Chem Biol Interact; 2017 Apr; 268():1-12. PubMed ID: 28219639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule.
    da Silva DAM; Santana FR; Katz S; Garcia DM; Teixeira D; Longo-Maugéri IM; Barbiéri CL
    Front Immunol; 2020; 11():345. PubMed ID: 32194563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
    Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
    Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
    dos Santos AO; Costa MA; Ueda-Nakamura T; Dias-Filho BP; da Veiga-Júnior VF; de Souza Lima MM; Nakamura CV
    Exp Parasitol; 2011 Oct; 129(2):145-51. PubMed ID: 21771592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
    Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
    J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
    Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
    J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leishmanicidal activity of Himatanthus sucuuba latex against Leishmania amazonensis.
    Soares DC; Andrade AL; Delorenzi JC; Silva JR; Freire-de-Lima L; Falcão CA; Pinto AC; Rossi-Bergmann B; Saraiva EM
    Parasitol Int; 2010 Jun; 59(2):173-7. PubMed ID: 20096374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
    Emiliano YSS; Almeida-Amaral EE
    J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load.
    da Fonseca-Martins AM; Ramos TD; Pratti JES; Firmino-Cruz L; Gomes DCO; Soong L; Saraiva EM; de Matos Guedes HL
    Sci Rep; 2019 Dec; 9(1):20275. PubMed ID: 31889072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
    Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
    Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.